MajorClass III antiarrhythmic, selective IKr blocker×Third-generation fluoroquinolone
Updated · Methodology
Mechanism
Dofetilide is a class III antiarrhythmic. It blocks the rapid component of the delayed rectifier potassium current (IKr), and QT prolongation depends directly on its plasma concentration (dofetilide label, US Food and Drug Administration, FDA). Some fluoroquinolones, including levofloxacin, have been associated with QT prolongation and infrequent cases of arrhythmia. Rare post-marketing cases of torsade de pointes have been reported (levofloxacin FDA label). The effects of the two drugs on QT may therefore add up. The documents describe no pharmacokinetic interaction for this pair. Dofetilide does not inhibit cytochrome P450 enzymes (dofetilide FDA label). Levofloxacin is metabolised very little and leaves the body mainly through the kidneys (levofloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The Medication Guide of the US dofetilide label lists the warning signs of a dangerous arrhythmia: feeling faint, dizziness and a fast heartbeat. It warns that torsade de pointes can lead to death (dofetilide label, US Food and Drug Administration, FDA). In people with supraventricular arrhythmias who took dofetilide, torsade de pointes occurred in 0.8%, mostly within the first three days of treatment. Low potassium or magnesium increases the risk (FDA). The adverse reactions of levofloxacin include ventricular tachycardia that may lead to cardiac arrest, ventricular arrhythmias and torsade de pointes. They have been reported mainly in people with risk factors for QT prolongation (levofloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
Avoid the combination. The US levofloxacin label says to avoid levofloxacin in patients receiving class IA or class III antiarrhythmics (levofloxacin label, US Food and Drug Administration, FDA). According to its own label, dofetilide is a class III antiarrhythmic (dofetilide FDA label). The US dofetilide label does not recommend dofetilide with other drugs that prolong the QT interval and names certain fluoroquinolones among them (dofetilide FDA label). The Spanish levofloxacin summary of product characteristics (SmPC) is less strict: it advises caution with QT-prolonging drugs, including class IA and class III antiarrhythmics (levofloxacin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is not in the Spanish medicines register CIMA. No document contraindicates the combination. If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug. When restarting dofetilide, keep the patient for at least three days in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and perform cardiac resuscitation (FDA). Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) is above 440 ms (500 ms with ventricular conduction abnormalities). Stop dofetilide if the QTc exceeds 500 ms (550 ms with such abnormalities). Keep potassium in the normal range before and during treatment (FDA). Use levofloxacin with caution in congenital long QT syndrome, uncorrected low potassium or magnesium and heart disease. Older people and women may be more sensitive to QT-prolonging drugs (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Levofloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 5c6c117c-9d91-48f4-9aaa-ee70b99218c2, version 3, 06/2026, section 5.11 (Prolongation of the QT Interval)
- FDA: TIKOSYN (dofetilide) capsules prescribing information (2026)– FDA, DailyMed setid 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (Pfizer), revisión 04/2026 (versión 30), Boxed Warning, Contraindications, Warnings (Ventricular Arrhythmia, Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents), Precautions (Drug-Drug Interactions), Dosage and Administration
- AEMPS: Ficha técnica: Levofloxacino, Tavanic 500 mg (nº registro 62065), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62065 (Tavanic 500 mg comprimidos recubiertos con película, Sanofi Aventis), revisión 08/2026, secciones 4.3, 4.4, 4.5, 4.8 y 4.9